Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Vesicular monoamine transporter inhibitors versus placebo for antipsychotic‐induced tardive dyskinesia

Información

DOI:
https://doi.org/10.1002/14651858.CD012986Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 22 marzo 2018see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Esquizofrenia

Copyright:
  1. Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Boris Karl

    Kimbolton School, Huntingdon, UK

  • Hanna Bergman

    Cochrane Response, Cochrane, London, UK

  • Sarah Abd El Sayed

    The Pear Tree Centre, Worcestershire Health and Care NHS Trust, Redditch, UK

  • Clive E Adams

    Correspondencia a: Cochrane Schizophrenia Group, The University of Nottingham, Nottingham, UK

    [email protected]

Contributions of authors

BK ‐ drafted the protocol

HB ‐ drafted the protocol

SAS ‐ checked final version

CEA ‐ drafted the protocol

Sources of support

Internal sources

  • Kimbolton School, UK.

  • University of Nottingham, UK.

External sources

  • No sources of support supplied

Declarations of interest

BK ‐ None

HB ‐ Hanna Bergman has a consultancy contract with Cochrane Response, an evidence services unit operated by the Cochrane Collaboration, to carry out systematic reviews on various topics.

SAS ‐ None

CEA ‐ None

Acknowledgements

The Cochrane Schizophrenia Group Editorial Base at The University of Nottingham, Nottingham, UK, produces and maintains standard text for use in the Methods section of their reviews. We have used this text as the basis of what appears here and adapted it as required.

We thank Christina Kaewchaluay for peer reviewing this protocol.

Version history

Published

Title

Stage

Authors

Version

2018 Mar 22

Vesicular monoamine transporter inhibitors versus placebo for antipsychotic‐induced tardive dyskinesia

Protocol

Boris Karl, Hanna Bergman, Sarah Abd El Sayed, Clive E Adams

https://doi.org/10.1002/14651858.CD012986

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Deutetrabenazine (3R,11bR)‐3‐(2‐methylpropyl)‐9,10‐bis(trideuteriomethoxy)‐1,3,4,6,7,11b‐hexahydrobenzo[a]quinolizin‐2‐one
Figuras y tablas -
Figure 1

Deutetrabenazine (3R,11bR)‐3‐(2‐methylpropyl)‐9,10‐bis(trideuteriomethoxy)‐1,3,4,6,7,11b‐hexahydrobenzo[a]quinolizin‐2‐one

Ir a la figura del protocoloAbrir en una pestaña nueva

Valbenazine (2R,3R,11bR)‐3‐isobutyl‐9,10‐dimethoxy‐1,3,4,6,7,11b‐hexahydro‐2H‐pyrido[2,1‐a]isoquinolin‐2‐yl L‐valinate)
Figuras y tablas -
Figure 2

Valbenazine (2R,3R,11bR)‐3‐isobutyl‐9,10‐dimethoxy‐1,3,4,6,7,11b‐hexahydro‐2H‐pyrido[2,1‐a]isoquinolin‐2‐yl L‐valinate)

Ir a la figura del protocoloAbrir en una pestaña nueva

Message from one of the participants in the public and patient involvement consultation of service‐user perspectives on tardive dyskinesia research
Figuras y tablas -
Figure 3

Message from one of the participants in the public and patient involvement consultation of service‐user perspectives on tardive dyskinesia research

Ir a la figura del protocoloAbrir en una pestaña nueva
Table 1. Other Cochrane Reviews in this series

Interventions

Current reference(s) (updates underway)

Anticholinergic medication

Soares 2000; Soares‐Weiser 1997

Benzodiazepines

Bhoopathi 2006

Calcium‐channel blockers

Essali 2011

Cholinergic medication

Tammenmaa 2002

Gamma‐aminobutyric acid agonists

Alabed 2011

Miscellaneous treatments

Soares‐Weiser 2003

Antipsychotic reduction orcessation, or both, and neuroleptics

Soares‐Weiser 2006

Non‐neuroleptic catecholaminergic drugs

El‐Sayeh 2006

Vitamin E

Soares‐Weiser 2011

Figuras y tablas -
Table 1. Other Cochrane Reviews in this series
Ir a la tabla del protocolo